Cellular immunity to merozoite surface protein 2 (FC27 and 3D7) in Papua New Guinean children. Temporal variation and relation to clinical and parasitological status
- Author(s)
- AlYaman, F; Genton, B; Taraika, J; Anders, R; Alpers, MP;
- Details
- Publication Year 1997-05,Volume 19,Issue #5,Page 207-214
- Journal Title
- PARASITE IMMUNOLOGY
- Publication Type
- Journal Article
- Abstract
- A prospective study in 207 children aged 0.5-15 years was carried out in a highly endemic area of Papua New Guinea to examine the relationship between cellular responses to Plasmodium falciparum merozoite surface protein 2 (MSP2) and malaria infection and morbidity. In vitro proliferation, IFN-gamma and IL-4 induction were measured against two recombinant proteins of MSP2, FC27 and 3D7 as well as against a form of the 3D7 MSP2 lacking the central repetitive sequences (d3D7). The prevalence of proliferative response was generally low, 6% for FC27, 9% for 3D7 and 11% for d3D7. A higher prevalence of IL-4 response was obtained being 27% for FC27, 34% for 3D7 and 30% for d3D7 while the prevalence of IFN-gamma response was 13%, 15% and 18%, respectively. There was no correlation between age and proliferative responses; in contrast cytokine production increased with age for all three anti gens. When proliferation or stimulation of either cytokine was used to assess T-cell activation the frequency of responders increased to 39%, 47% and 46% for FC27, 3D7 and d3D7 respectively. Analysis of the relation of T cell responses to concurrent infection and morbidity showed that lymphoproliferative response only to d3D7 was significantly associated with parasitaemia; while lymphoproliferative responses to all 3 MSP2 antigens were highest in the group of clinical malaria cases. There was no significant correlation between proliferation or cytokine production to MSP2 and concurrent or subsequent malaria morbidity.
- Publisher
- BLACKWELL SCIENCE LTD
- Keywords
- PLASMODIUM-FALCIPARUM ANTIGENS; EAST SEPIK PROVINCE; MALARIA TRANSMISSION; T-CELLS; HUMORAL RESPONSE; VACCINE TRIALS; WOSERA AREA; EPIDEMIOLOGY; ANTIBODIES; PF155/RESA
- Publisher's Version
- https://doi.org/10.1046/j.1365-3024.1997.d01-198.x
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 1997-05-01 12:00:00